Effect of presenilin mutations on APP cleavage; Insights into the pathogenesis of FAD

Frontiers in Aging Neuroscience

Volumn 8, Issue MAR, 2016, Pages

  Li, Nuomin ^a   Liu, Kefu ^a   Qiu, Yunjie ^a   Ren, Zehui ^a   Dai, Rongji ^a   Deng, Yulin ^a   Qing, Hong ^a  

^a BEIJING INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Amyloid peptide; Familial Alzheimer's disease; Presenilin1; secretase

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; PRESENILIN; TETRAPEPTIDE; TRIPEPTIDE;

ALZHEIMER DISEASE; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; PATHOGENESIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING;

EID: 84964686873     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2016.00051     Document Type: Article

References (44)

1. Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., et al. (2008). Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59, 43-55. doi: 10.1016/j.neuron.2008.06.018.
2. Amtul, Z., Lewis, P. A., Piper, S., Crook, R., Baker, M., Findlay, K., et al. (2002). A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch. Neurobiol. Dis. 9, 269-273. doi: 10.1006/nbdi.2001.0473.
3. Barnwell, E., Padmaraju, V., Baranello, R., Pacheco-Quinto, J., Crosson, C., Ablonczy, Z., et al. (2014). Evidence of a novel mechanism for partial gamma-secretase inhibition induced paradoxical increase in secreted amyloid beta protein. PLoS ONE 9:e91531. doi: 10.1371/journal.pone.0091531.
4. Bentahir, M., Nyabi, O., Verhamme, J., Tolia, A., Horre, K., Wiltfang, J., et al. (2006). Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J. Neurochem. 96, 732-742. doi: 10.1111/j.1471-4159.2005.03578.x.
5. Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., et al. (1992). Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J. Biol. Chem. 267, 546-554.
6. Cacquevel, M., Aeschbach, L., Houacine, J., and Fraering, P. C. (2012). Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified gamma-secretase complexes. PLoS ONE 7:e35133. doi: 10.1371/journal.pone.0035133.
7. Chow, V. W., Mattson, M. P., Wong, P. C., and Gleichmann, M. (2010). An overview of APP processing enzymes and products. Neuromol. Med. 12, 1-12. doi: 10.1007/s12017-009-8104-z.
8. Christensen, M. A., Zhou, W., Qing, H., Lehman, A., Philipsen, S., and Song, W. (2004). Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol. Cell Biol. 24, 865-874. doi: 10.1128/MCB.24.2.865-874.2004.
9. Czirr, E., Cottrell, B. A., Leuchtenberger, S., Kukar, T., Ladd, T. B., Esselmann, H., et al. (2008). Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase. J. Biol. Chem. 283, 17049-17054. doi: 10.1074/jbc.M802912200.
10. Dermaut, B., Kumar-Singh, S., Engelborghs, S., Theuns, J., Rademakers, R., Saerens, J., et al. (2004). A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann. Neurol. 55, 617-626. doi: 10.1002/ana.20083.
11. Fernandez, M. A., Klutkowski, J. A., Freret, T., and Wolfe, M. S. (2014). Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid beta-peptides (Abeta) by gamma-Secretase to Increase 42-to-40-Residue Abeta. J. Biol. Chem. 289, 31043-31052. doi: 10.1074/jbc.M114.581165.
12. Francis, R., McGrath, G., Zhang, J., Ruddy, D. A., Sym, M., Apfeld, J., et al. (2002). aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of beta APP, and presenilin protein accumulation. Dev. Cell 3, 85-97. doi: 10.1016/S1534-5807(02)00189-2.
13. Goutte, C., Tsunozaki, M., Hale, V. A., and Priess, J. R. (2002). APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc. Natl. Acad. Sci. U.S.A. 99, 775-779. doi: 10.1073/pnas.022523499.
14. He, G., Luo, W., Li, P., Remmers, C., Netzer, W. J., Hendrick, J., et al. (2010). Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467, 95-98. doi: 10.1038/nature09325.
15. Henricson, A., Kall, L., and Sonnhammer, E. L. (2005). A novel transmembrane topology of presenilin based on reconciling experimental and computational evidence. FEBS J. 272, 2727-2733. doi: 10.1111/j.1742-4658.2005.04691.x.
16. Houlden, H., Crook, R., Dolan, R. J., McLaughlin, J., Revesz, T., and Hardy, J. (2001). A novel presenilin mutation (M233V) causing very early onset Alzheimer's disease with Lewy bodies. Neurosci. Lett. 313, 93-95. doi: 10.1016/S0304-3940(01)02254-6.
17. Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., et al. (2012). A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99. doi: 10.1038/nature11283.
18. Kakuda, N., Funamoto, S., Yagishita, S., Takami, M., Osawa, S., Dohmae, N., et al. (2006). Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. J. Biol. Chem. 281, 14776-14786. doi: 10.1074/jbc.M513453200.
19. Kim, H., Ki, H., Park, H. S., and Kim, K. (2005). Presenilin-1 D257A and D385A mutants fail to cleave Notch in their endoproteolyzed forms, but only presenilin-1 D385A mutant can restore its gamma-secretase activity with the compensatory overexpression of normal C-terminal fragment. J. Biol. Chem. 280, 22462-22472. doi: 10.1074/jbc.M502769200.
20. Kim, J., Bagyinszky, E., Chang, Y. H., Choe, G., Choi, B. O., An, S. S., et al. (2012). A novel PSEN1 H163P mutation in a patient with early-onset Alzheimer's disease: clinical, neuroimaging, and neuropathological findings. Neurosci. Lett. 530, 109-114. doi: 10.1016/j.neulet.2012.09.040.
21. Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., et al. (2007). Abeta40 inhibits amyloid deposition in vivo. J. Neurosci. 27, 627-633. doi: 10.1523/JNEUROSCI.4849-06.2007.
22. Kim, S. H., Leem, J. Y., Lah, J. J., Slunt, H. H., Levey, A. I., Thinakaran, G., et al. (2001). Multiple effects of aspartate mutant presenilin 1 on the processing and trafficking of amyloid precursor protein. J. Biol. Chem. 276, 43343-43350. doi: 10.1074/jbc.M108245200.
23. Kretner, B., Fukumori, A., Gutsmiedl, A., Page, R. M., Luebbers, T., Galley, G., et al. (2011). Attenuated Abeta42 responses to low potency gamma-secretase modulators can be overcome for many pathogenic presenilin mutants by second-generation compounds. J. Biol. Chem. 286, 15240-15251. doi: 10.1074/jbc.M110.213587.
24. Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., et al. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357. doi: 10.1038/nature04533.
25. Li, Y., Zhou, W., Tong, Y., He, G., and Song, W. (2006). Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription. FASEB J. 20, 285-292. doi: 10.1096/fj.05-4986com.
26. Okochi, M., Tagami, S., Yanagida, K., Takami, M., Kodama, T. S., Mori, K., et al. (2013). gamma-secretase modulators and presenilin 1 mutants act differently on presenilin/gamma-secretase function to cleave Abeta42 and Abeta43. Cell Rep. 3, 42-51. doi: 10.1016/j.celrep.2012.11.028.
27. Olsson, F., Schmidt, S., Althoff, V., Munter, L. M., Jin, S., Rosqvist, S., et al. (2014). Characterization of intermediate steps in amyloid beta (Abeta) production under near-native conditions. J. Biol. Chem. 289, 1540-1550. doi: 10.1074/jbc.M113.498246.
28. Piccini, A., Zanusso, G., Borghi, R., Noviello, C., Monaco, S., Russo, R., et al. (2007). Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype. Arch. Neurol. 64, 738-745. doi: 10.1001/archneur.64.5.738.
29. Qing, H., Zhou, W., Christensen, M. A., Sun, X., Tong, Y., and Song, W. (2004). Degradation of BACE by the ubiquitin-proteasome pathway. FASEB J. 18, 1571-1573. doi: 10.1096/fj.04-1994fje.
30. Qi-Takahara, Y., Morishima-Kawashima, M., Tanimura, Y., Dolios, G., Hirotani, N., Horikoshi, Y., et al. (2005). Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J. Neurosci. 25, 436-445. doi: 10.1523/JNEUROSCI.1575-04.2005.
31. Raux, G., Gantier, R., Thomas-Anterion, C., Boulliat, J., Verpillat, P., Hannequin, D., et al. (2000). Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation. Neurology 55, 1577-1578. doi: 10.1212/WNL.55.10.1577.
32. Schagger, H. (2006). Tricine-SDS-PAGE. Nat. Protoc. 1, 16-22. doi: 10.1038/nprot.2006.4.
33. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842. doi: 10.1038/nm1782.
34. Shen, J., and Kelleher, R. J. III. (2007). The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc. Natl. Acad. Sci. U.S.A. 104, 403-409. doi: 10.1073/pnas.0608332104.
35. Shioi, J., Georgakopoulos, A., Mehta, P., Kouchi, Z., Litterst, C. M., Baki, L., et al. (2007). FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta. J. Neurochem. 101, 674-681. doi: 10.1111/j.1471-4159.2006.04391.x.
36. Spasic, D., Tolia, A., Dillen, K., Baert, V., De Strooper, B., Vrijens, S., et al. (2006). Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway. J. Biol. Chem. 281, 26569-26577. doi: 10.1074/jbc.M600592200.
37. Sun, X., Chen, W. D., and Wang, Y. D. (2015). beta-Amyloid: the key peptide in the pathogenesis of Alzheimer's disease. Front. Pharmacol. 6:221. doi: 10.3389/fphar.2015.00221.
38. Takami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., et al. (2009). gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J. Neurosci. 29, 13042-13052. doi: 10.1523/JNEUROSCI.2362-09.2009.
39. Thinakaran, G., and Koo, E. H. (2008). Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283, 29615-29619. doi: 10.1074/jbc.R800019200.
40. Uttner, I., Kirchheiner, J., Tumani, H., Mottaghy, F. M., Lebedeva, E., Ozer, E., et al. (2010). A novel presenilin1 mutation (Q223R) associated with early onset Alzheimer's disease, dysarthria and spastic paraparesis and decreased Abeta levels in CSF. Eur. J. Neurol. 17, 631-633. doi: 10.1111/j.1468-1331.2009.02810.x.
41. Wanngren, J., Lara, P., Ojemalm, K., Maioli, S., Moradi, N., Chen, L., et al. (2014). Changed membrane integration and catalytic site conformation are two mechanisms behind the increased Abeta42/Abeta40 ratio by presenilin 1 familial Alzheimer-linked mutations. FEBS Open. Biol. 4, 393-406. doi: 10.1016/j.fob.2014.04.006.
42. Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., and Selkoe, D. J. (1999). Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398, 513-517. doi: 10.1038/19077.
43. Wu, L., Rosa-Neto, P., Hsiung, G. Y., Sadovnick, A. D., Masellis, M., Black, S. E., et al. (2012). Early-onset familial Alzheimer's disease (EOFAD). Can. J. Neurol. Sci. 39, 436-445. doi: 10.1017/S0317167100013949.
44. Yu, G., Nishimura, M., Arawaka, S., Levitan, D., Zhang, L., Tandon, A., et al. (2000). Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature 407, 48-54. doi: 10.1038/35024009